Critical Care · 2021 · 194 citations · 46 references
MedicineInternal MedicineClinical Decision SupportEvidence-based PracticePulmonologyAcute Respiratory Distress SyndromeAcute Respiratory FailureClinical Practice GuidelinesGuideline ImplementationRespiratory DiseaseRespiratory Failure ManagementAcute Respiratory Distress Syndrome AssessmentAcute Respiratory Failure AssessmentCovid-19-associated Acute Respiratory Distress SyndromeLikert Scale DesignLikert Scale DevelopmentMultiple-choice QuestionsRespiratory Disease Management
Abstract Background Coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented pressure on healthcare system globally. Lack of high-quality evidence on the respiratory management of COVID-19-related acute respiratory failure (C-ARF) has resulted in wide variation in clinical practice. Methods Using a Delphi process, an international panel of 39 experts developed clinical practice statements on the respiratory management of C-ARF in areas where evidence is absent or limited. Agreement was defined as achieved when > 70% experts voted for a given option on the Likert scale statement or > 80% voted for a particular option in multiple-choice questions. Stability was assessed between the two concluding rounds for each statement, using the non-parametric Chi-square ( χ 2 ) test ( p < 0·05 was considered as unstable). Results Agreement was achieved for 27 (73%) management strategies which were then used to develop expert clinical practice statements. Experts agreed that COVID-19-related acute respiratory distress syndrome (ARDS) is clinically similar to other forms of ARDS. The Delphi process yielded strong suggestions for use of systemic corticosteroids for critical COVID-19; awake self-proning to improve oxygenation and high flow nasal oxygen to potentially reduce tracheal intubation; non-invasive ventilation for patients with mixed hypoxemic-hypercapnic respiratory failure; tracheal intubation for poor mentation, hemodynamic instability or severe hypoxemia; closed suction systems; lung protective ventilation; prone ventilation (for 16–24 h per day) to improve oxygenation; neuromuscular blocking agents for patient-ventilator dyssynchrony; avoiding delay in extubation for the risk of reintubation; and similar timing of tracheostomy as in non-COVID-19 patients. There was no agreement on positive end expiratory pressure titration or the choice of personal protective equipment. Conclusion Using a Delphi method, an agreement among experts was reached for 27 statements from which 20 expert clinical practice statements were derived on the respiratory management of C-ARF, addressing important decisions for patient management in areas where evidence is either absent or limited. Trial registration : The study was registered with Clinical trials.gov Identifier: NCT04534569.
46
Dexamethasone in Hospitalized Patients with Covid-19.
Peter Horby, Wei Shen Lim, Jonathan Emberson et al. · DiRROS repository (University of Maribor) · 2020 · 8K citations · Full text
Prone Positioning in Severe Acute Respiratory Distress Syndrome
Claude Guérin, Jean Reignier, Jean‐Christophe Richard et al. · New England Journal of Medicine · 2013 · 4.1K citations · Full text
Annemarie B Docherty, Ewen M. Harrison, Christopher Green et al. · BMJ · 2020 · 3.6K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +13